Anzeige
Mehr »
Mittwoch, 13.05.2026 - Börsentäglich über 12.000 News
Kann Inspiration Mining die nächste 1.000 % Chance werden? Das Bohrprogramm startet in wenigen Tagen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DA81 | ISIN: US65344E1073 | Ticker-Symbol:
NASDAQ
12.05.26 | 21:42
0,586 US-Dollar
-3,21 % -0,019
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
NEXGEL INC Chart 1 Jahr
5-Tage-Chart
NEXGEL INC 5-Tage-Chart

Aktuelle News zur NEXGEL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiNEXGEL, INC. - 8-K, Current Report1
NEXGEL Aktie jetzt für 0€ handeln
DiNEXGEL, INC.: NEXGEL To Report First Quarter 2026 Financial Results on May 15th2
06.05.NEXGEL, INC.: NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience, to Board of Directors2
30.04.NEXGEL, INC. - 10-K/A, Annual Report1
30.04.NEXGEL, INC. - 8-K, Current Report11
22.04.NEXGEL expects pro forma annual revenue of roughly $35M following Celularity wound segment acquisition3
21.04.NEXGEL, INC. - 8-K, Current Report-
21.04.NEXGEL schließt Biomaterialien-Deal mit Celularity ab und sichert sich 5,5 Millionen US-Dollar6
21.04.Celularity Inc.: Celularity Announces Closing of Transaction with NexGel162FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, today announced the closing of...
► Artikel lesen
17.04.NEXGEL, INC.: NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET1
05.04.Nexgel: EPS verfehlt Schätzungen um 0,09 $ - Umsatz schlechter als erwartet11
31.03.NEXGEL, INC. - 10-K, Annual Report-
25.03.NEXGEL, INC.: NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st1
12.03.NEXGEL, INC.: NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products435Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio ...
► Artikel lesen
12.03.Celularity Inc.: Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities288Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications.Three pipeline...
► Artikel lesen
10.03.NEXGEL, INC. - 8-K, Current Report1
10.03.NexGel to license, acquire regenerative biomaterial products5
10.03.NexGel übernimmt Biomaterial-Portfolio von Celularity und erwartet sofortige Profitabilität15
10.03.NEXGEL, INC.: NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products270Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified...
► Artikel lesen
10.03.EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue4
Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1